CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your GIST must be confirmed by biopsy and advanced (spread or cannot be fully removed by surgery)
- Your cancer must have grown or you had side effects despite taking imatinib
- You must have had prior treatment for GIST (how much depends on which part of the trial)
- You must have at least one measurable tumor on imaging
- Your general health must allow for cancer treatment (ECOG score 0–2)
- Your blood work and organ function must be acceptable for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
This program provides access to bezuclastinib taken with sunitinib for people with advanced gastrointestinal stromal tumors (GIST) who cannot take imatinib or whose disease has worsened on imatinib. It aims to give treatment when no other clinical trial is available.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.